Introduction: Chimeric antigen receptor T cell (CAR T) agents have been commercially available since 2017 but have only just become available for patients with relapsed/refractory multiple myeloma (RRMM). Although idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are recommended in the fifth-line, there is data to support the use of CAR T agents in earlier lines. These data include the CARTITUDE-4 trial evaluating cilta-cel in patients with RRMM who have received 1-3 prior lines of therapy. The present study investigated the impact of CARTITUDE-4 among practicing oncologists/hematologists as it relates to use of CAR T therapies for patients with RRMM. Methods: In September 2023, US-based oncologists/hematologists (N=50) were invited to attend a live meeting to discuss abstracts presented at the American Society of Clinical Oncology 2023 conference. Demographics were collected in a premeeting survey. Participant perceptions of CARTITUDE-4 were captured via audience response system technology. Not all participants answered every question; responses were analyzed using descriptive statistics. Results: The factors that most impact respondents’ decision to refer/prescribe CAR T therapy include availability of spots at a CAR T center (23%) and patient comorbidities (20%). Respondents reported that their current treatment preference for a hypothetical 66-year-old male patient with triple-class refractory multiple myeloma in the fourth-line include cilta-cel (48%) and ide-cel (22%). However, after reviewing CARTITUDE-4, 88% of respondents indicated they would use cilta-cel to treat this same patient. Viewing CARTITUDE-4 also increased the number of respondents who indicated that they favor using CAR T agents in earlier lines of therapy for patients with RRMM. Interestingly, the majority of respondents indicated that they would sequence CAR T agents before a bispecific antibody (55%) after viewing CARTITUDE-4. Discussion: Overall, these data show that reviewing findings from CARTITUDE-4 had an impact on the perceptions and prescribing preferences of oncologists/hematologists. As interest in the use of CAR T agents in earlier lines grows, sequencing strategies for CAR T agents with other emerging treatment options―such as bispecific antibodies―becomes a critical topic. Future research at Cardinal Health aims to address the hurdles that hematologists face when making decisions for patients with RRMM within this rapidly evolving landscape.
HSR24-134: Perceptions of CARTITUDE-4 for Patients With Relapsed/Refractory Multiple Myeloma
Authors:
,
,
,
,
,
, and
Brooke Dulka
PhD
Brooke Dulka
Cardinal Health, Inc., Dublin, OH
Search for other papers by Brooke Dulka in
Current site
Google Scholar
PubMed
Search for other papers by Brooke Dulka in
Current site
Google Scholar
PubMed
Luke Jennings-Zhang
PharmD
Luke Jennings-Zhang
Cardinal Health, Inc., Dublin, OH
Search for other papers by Luke Jennings-Zhang in
Current site
Google Scholar
PubMed
Search for other papers by Luke Jennings-Zhang in
Current site
Google Scholar
PubMed
Samuel Baird
MPH
Samuel Baird
Cardinal Health, Inc., Dublin, OH
Search for other papers by Samuel Baird in
Current site
Google Scholar
PubMed
Search for other papers by Samuel Baird in
Current site
Google Scholar
PubMed
Robert N. Bone
PhD
Robert N. Bone
Cardinal Health, Inc., Dublin, OH
Search for other papers by Robert N. Bone in
Current site
Google Scholar
PubMed
Search for other papers by Robert N. Bone in
Current site
Google Scholar
PubMed
Yolaine Jeune-Smith
PhD
Yolaine Jeune-Smith
Cardinal Health, Inc., Dublin, OH
Search for other papers by Yolaine Jeune-Smith in
Current site
Google Scholar
PubMed
Search for other papers by Yolaine Jeune-Smith in
Current site
Google Scholar
PubMed
Muhamed Baljević
MD
Muhamed Baljević
Vanderbilt University, Nashville, TN
Search for other papers by Muhamed Baljević in
Current site
Google Scholar
PubMed
Search for other papers by Muhamed Baljević in
Current site
Google Scholar
PubMed
Bruce Feinberg
DO
Bruce Feinberg
Cardinal Health, Inc., Dublin, OH
Search for other papers by Bruce Feinberg in
Current site
Google Scholar
PubMed
Search for other papers by Bruce Feinberg in
Current site
Google Scholar
PubMed
© 2019-2024 National Comprehensive Cancer Network